Syringin reduced fibroblast senescence and fibrosis in IPF cell and mouse models
In an abstract integrating lung transcriptomic data from GTEx and nine IPF cohorts, senescent fibroblasts stood out as hubs; syringin attenuated fibroblast activation, senescence markers and fibrosis in TGFβ1-stimulated fibroblasts and bleomycin-treated mice, with CHK1 as a suggested mediator. [1]
Automatic summary · not editorially reviewed
The key findings
Lung transcriptomic data from GTEx and nine IPF cohorts showed strong concordance between age-related and IPF-related gene programs, and single-cell analyses identified senescent fibroblasts as hubs with elevated SASP factor expression. [1]
Syringin attenuated fibroblast activation, cellular senescence markers and pulmonary fibrosis in TGFβ1-stimulated fibroblasts and in a mouse model of bleomycin-induced pulmonary fibrosis. [1]
Docking and CETSA suggested a potential syringin–CHK1 interaction, and CHK1 knockdown partially abrogated syringin's effects on the ATR/CHK1-p53 cascade. [1]
The source at a glance
- Study type / format
- Abstract of a preclinical study integrating transcriptomic analyses with cell and mouse experiments
- Population / context
- Human lung tissue data from GTEx and nine IPF cohorts, IPF single-cell data, TGFβ1-stimulated fibroblasts and mice with bleomycin-induced pulmonary fibrosis
- Summary based on
- Study abstract
- Original publication
- October 1, 2026
Aging-linked gene programs in IPF lung data
The abstract describes idiopathic pulmonary fibrosis (IPF) as a progressive, fatal interstitial lung disease closely associated with aging. The authors integrated bulk lung transcriptomic data from the GTEx project and nine IPF cohorts with IPF single-cell RNA sequencing data. They report a pronounced aging-associated transcriptomic profile in IPF lungs and strong concordance between age-related and IPF-related gene programs. Single-cell analyses identified senescent fibroblast populations as key cellular hubs with elevated expression of senescence-associated secretory phenotype (SASP) factors. These are descriptive associations in tissue data, not evidence that aging causes IPF.
Supporting source [1]
Syringin effects in stimulated fibroblasts and mice
Syringin, a phenylpropanoid glycoside from Acanthopanax senticosus, was selected through a compound prioritization strategy using reversed gene expression scoring, network proximity, drug-likeness and toxicity evaluation. It was then tested in TGFβ1-stimulated fibroblasts and in a mouse model of bleomycin-induced pulmonary fibrosis. The abstract states that syringin consistently attenuated fibroblast activation, cellular senescence markers and pulmonary fibrosis both in vitro and in vivo. Mechanistically, it markedly reversed activation of replication stress-associated signaling pathways. Molecular docking and a cellular thermal shift assay suggested a potential interaction between syringin and CHK1, and CHK1 knockdown partially abrogated syringin's effects on the ATR/CHK1-p53 cascade.
Supporting source [1]
Preclinical scope of the syringin findings
The abstract frames syringin as a natural small molecule with anti-senescent and anti-fibrotic properties and as a possible therapeutic strategy for IPF. These results come from cell culture and a mouse model, not from people with IPF, so they do not show benefit for human patients. The CHK1 link rests partly on docking and CETSA, which suggest but do not confirm binding, and on partial effects of CHK1 knockdown. Only the abstract was reviewed; the full text was not reviewed, so details of sample sizes, follow-up and statistical uncertainty are not available here.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Results are from cell culture and a mouse model, not from people with IPF. Sample sizes, follow-up and statistical uncertainty are not reported in the abstract. Docking and CETSA suggest but do not confirm binding.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Wang Y, Yin G, Niu M, Wang W, Liao Z, Yang L, Wu C, Cao Y, Gao K, Dong Z. · europepmc.org · October 1, 2026